New entrants will propel ophthalmological disorders market to $26 billion by 2022; report

The ophthalmological disorders market, which is set to almost double from $13.7 billion in 2015 to $26 billion by 2022 at a compound annual growth rate (CAGR) of 9.48%, will see the entry of a range of new companies over the forecast period as the treatment space is transformed by patent expiries and new product entrants, a new analysis indicates.

According to business intelligence provider GBI Research’s latest report, the ophthalmology landscape, which covers glaucoma, age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and dry eye syndrome, will see top companies lose a degree of dominance as smaller, specialized companies gain ground.

Qaisrah Khalid, associate analyst for GBI Research, explains: “Four new companies – Ophthotech [Nasdaq: OPHT], Spark Therapeutics (Nasdaq: ONCE), Aerie Pharmaceuticals (Nasdaq: AERI), and Eleven Biotherapies (Nasdaq: EBIO) – will enter the market during the forecast period, and some of them are anticipated to become key players within this timeframe.